On the President’s Drug Cost Plan, Three Important Concerns

Part 3. Restricting access under Medicaid Is not the answer
This week, BIO launched a three-part blog series highlighting proposals in the Trump administration’s drug cost plan that could pose significant challenges for patients and their access to the medicines they need. Part 1 of the series looked at possible changes to the Medicare Part D prescription drug benefit program. Part 2 the series examined the possible consequences of shuffling certain drugs from Medicare Part B to Part D. In